TLL-018
Phase 3Small molecule
TLL-018 is one of 90 small molecule programs targeting Chronic Spontaneous Urticaria (CSU). It is currently in Phase 3.
4
Indications
7
Total Trials
4
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
242 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Lutathera
NovartisPhase 3
S1,
CChinese Academy of Medical Sciences
Phase 3
TLL-018
HHangzhou Highlightll Pharmaceutical Co., Ltd
Phase 3
HSK39297
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Efsubaglutide Alfa
SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 3
AVTX-803
AAUG Therapeutics
Phase 3
DFL24498
DDompé Farmaceutici S.p.A
Phase 3
EB-1020
OtsukaPhase 3
QL0605
Qilu Pharmaceutical Co., Ltd.Phase 3
Lenzumestrocel
CCorestemchemon, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rheumatoid Arthritis2 trials
Tolerance1 trial
Chronic Spontaneous Urticaria (CSU)1 trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/IIa Clinical Trial Assessing the Rapid Onset Characteristics of TLL-018 in Subjects With Moderate-to-Severe Chronic Spontaneous Urticaria Who Fail to Achieve Adequate Control With Second-Generation H1 Antihistamines
Not yet recruiting·HHangzhou Highlightll Pharmaceutical Co., Ltd·Preclinical·NCT07665996·36 enrolled
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TLL-018. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details